Jump to Main Content
Prevalence and genotype of Mycoplasma bovis in beef cattle after arrival at a feedlot
- Castillo-Alcala, Fernanda, Bateman, Kenneth G., Cai, Hugh Y., Schott, Courtney R., Parker, Lois, Clark, Mary Ellen, McRaild, Patricia, McDowall, Rebecca M., Foster, Robert A., Archambault, Marie, Caswell, Jeff L.
- American journal of veterinary research 2012 v.73 no.12 pp. 1932-1943
- Mycoplasma bovis, amplified fragment length polymorphism, beef cattle, calves, feedlots, genotype, lungs, pneumonia, quantitative polymerase chain reaction
- Objective: To determine the prevalence of Mycoplasma bovis infection in the lungs of cattle at various times after arrival at a feedlot, to measure the relationship between clinical disease status and the concentration and genotype of M bovis within the lungs, and to investigate changes in the genotype of M bovis over time. Sample: Bronchoalveolar lavage fluid (BALF) from 328 healthy or pneumonic beef cattle and 20 M bovis isolates obtained from postmortem samples. Procedures: The concentration of M bovis in BALF was determined via real-time PCR assays, and M bovis isolates from BALF were genotyped via amplified fragment length polymorphism (AFLP) analysis. Results: Prevalence of M bovis in BALF was 1 of 60 (1.7%) at arrival to a feedlot and 26 of 36 (72.2%) and 36 of 42 (85.7%) at ≤ 15 days and 55 days after arrival, respectively. Neither the concentration nor the AFLP type of M bovis in BALF was correlated with clinical disease status. The M bovis AFLP type differed between early and later sampling periods in 14 of 17 cattle. Conclusions and Clinical Relevance: The findings implied spread of M bovis among calves and suggested that host factors and copathogens may determine disease outcomes in infected calves. Chronic pulmonary infection with M bovis may represent a dynamic situation of bacterial clearance and reinfection with strains of different AFLP type, rather than continuous infection with a single clone. These findings impact our understanding of why cattle with chronic pneumonia and polyarthritis syndrome inadequately respond to antimicrobial treatment.